logo-loader
viewNetscientific PLC

NetScientific unaware of any reason behind recent share price jump

The company is currently trying to reduce its costs “significantly” in order to invest as much of its remaining cash as possible into its portfolio companies

Scientist
NetScientific invests in medical and healthcare businesses

NetScientific PLC (LON:NSCI) has said it is unaware of any reason behind a 247% surge in its share price on Wednesday to 12.5p.

The medical research investor added that despite the increase the shares were still at discount to their price prior to 20 December when it announced a strategic review that included options to delist from AIM and taking the company private, although at the start of March the firm said more than 30% of shareholders indicated they would vote against these options.

READ: Netscientific expects shareholders to reject plan to delist from AIM and become private company

The company is currently trying to reduce its costs “significantly” in order to invest as much of its remaining cash as possible into its portfolio companies.

In early trading Thursday, shares were up 13.6% at 14.2p.

Quick facts: Netscientific PLC

Price: 6 GBX

AIM:NSCI
Market: AIM
Market Cap: £4.71 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Netscientific PLC named herein, including the promotion by the Company of Netscientific PLC in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

Top stories from the Proactive Investors UK newsroom: ANGLE PLC (LON:AGL) has received positive results from its Parsortix FDA clinical study for metastatic breast cancer. The 400-subject clinical study will support an application for Class II regulatory clearance for Parsortix in the...

on 31/5/19

2 min read